2, such as normal brain aging3, neurodegenerative disorders such as Alzheimer’s disease (AD)4, and brain cancer5. Based on magnetic resonance imaging (MRI), AI-derived measures of the human brain age6,7,8have emerged as a valuable biomarker for evaluating ...
The specific mechanisms underlying the therapeutic effects of DBS in SUDs treatment have not yet been fully elucidated. However, from the perspective of leveraging the progress in DBS for other neurologic conditions, such as major depressive disorder and Parkinson’s disease, DBS is believed to exert...
1990-2017 Global Disparities in Parkinson Disease Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension Mass Violence and the Complex Spectrum of Mental Illness and Mental Functioning Neuropsychiatry Sequelae of COVID-19 A New Framework for Dementia Nomenclature Organizatio...
Aldaz T, Nigro P, Sánchez-Gómez A et al (2019) Non-motor symptoms in Huntington’s disease: a comparative study with Parkinson’s disease. J Neurol 266:1340–1350. https://doi.org/10.1007/s00415-019-09263-7 Article PubMed Google Scholar Andersen JV, Skotte NH, Aldana BI et al (...
After including total brain volume, correlations between fixel measures and GA at birth, days on TPN, birthweight z-scores and differences between male and female subjects were no longer statistically significant. However, brain volume was strongly correlated with age at scan and the perinatal risk...
Comprehensive studies using resting state fMRI and a graph theory approach have shown that the statistical properties of endogenous fluctuations are modulated in Alzheimer’s disease47, Parkinson’s disease48, autism spectrum disorders49 and multiple sclerosis50. In this study, in the allodynia mouse ...
(methamphetamine) users revealed higher MD in regions of the dopaminergic system.37 Further, an intervention study of Parkinson's disease revealed that adminis- tration of the dopamine agonist L-dopa led to increased MD in regions of the dopaminergic system.14 Therefore, a greater amount of VGP ...
activators of HDAC1 yielded exifone as an HDAC activator and a strong candidate for such a therapeutic strategy (Supplementary Fig.9a)52. Exifone has also been shown to have pro-cognitive effects in animal models and in patients with Alzheimer’s-type dementia and Parkinson’s disease53,54,55...